Illumina Inc. (ILMN)
ILMN (NASDAQ:Drugs)
$70.69
-1.89
-2.60%
Today's Range: 69.82 - 72.68 |
ILMN Avg Daily Volume: 1,352,700
| Last Update: 05/22/13 - 4:00 PM EDT |
| Volume: 2,142,042 |
| YTD Performance: 31.46%
|
| Open: $72.38 |
| Previous Close: $72.58 |
| 52 Week Range: $37.77 -
$77.11 |
| Oustanding Shares: 124,378,537 |
| Market Cap: 9,089,583,484 |
6-Month Chart
TheStreet Ratings Grade for ILMN
| Buy |
Hold
|
Sell
|
| A+ |
A |
A- |
B+ |
B |
B- |
C+ |
C |
C- |
D+ |
D |
D- |
E+ |
E |
E- |
F |
Analysts Ratings
| Historical Rec |
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
| Strong Buy |
8 |
8 |
8 |
7 |
| Moderate Buy |
0 |
0 |
0 |
0 |
| Hold |
7 |
7 |
7 |
8 |
| Moderate Sell |
1 |
1 |
1 |
1 |
| Strong Sell |
0 |
0 |
0 |
0 |
| Mean Rec. |
2.06 |
2.06 |
2.06 |
2.19 |
| Latest Dividend: |
0.00 |
| Latest Dividend Yield: |
0.00% |
| Dividend Ex-Date: |
12/31/69 |
| Price Earnings Ratio: |
97.44 |
|
| Price Earnings Comparisons: |
| ILMN |
Sector Avg. |
S&P 500 |
| 97.44 |
97.40 |
17.70 |
| Price Performance History (%Change): |
| 3 Mo |
1 Yr |
3 Y |
|
49.72%
|
69.38%
|
85.15%
|
|
| GROWTH |
12 Mo |
3 Yr |
CAGR |
| Revenue |
8.80 |
0.72 |
0.20 |
| Net Income |
74.60 |
1.09 |
0.28 |
| EPS |
82.30 |
1.08 |
0.27 |
| Earnings for ILMN: |
| EBITDA |
0.31B |
| Revenue |
1.15B |
|
Average Earnings Estimates
;Qtr (09/13);FY (12/13);FY (12/14)&HEADING_LIST1=Qtr (06/12);Qtr (09/12);FY (12/12);FY (12/13)) |
|
| Average Estimate |
$0.39 |
$0.40 |
$1.60 |
$1.97 |
| Number of Analysts |
14 |
13 |
2 |
15 |
| High Estimate |
$0.42 |
$0.44 |
$1.61 |
$2.10 |
| Low Estimate |
$0.32 |
$0.35 |
$1.58 |
$1.78 |
| Prior Year |
$0.40 |
$0.32 |
$1.59 |
$1.60 |
| Growth Rate (Year over Year) |
-2.32% |
24.52% |
0.31% |
23.55% |
Apr 23, 2013 | 8:07 AM EDT
ILMN estimates were raised through 2015, Credit Suisse said. Company can likely gain market share from its top competitor. Outperform r...
Apr 23, 2013 | 8:00 AM EDT
ILMN earnings estimates increased through 2014 given the first quarter beat, said UBS. The current earnings guidance seems conservative...
Mar 01, 2013 | 8:16 AM EST
ILMN was upgraded to Buy from Neutral, UBS said. $61 price target. Re focus on commecial strength should drive upside.
| Feb 11, 2013 | 1:30 PM EST
These two stocks have been consolidating and now appear ready to move in opposite directions.
Jan 29, 2013 | 7:09 AM EST
Shares of ILMN now seen reaching $59, according to Credit Suisse. Estimates also reduced, as the company lowered its guidance.
Jan 04, 2013 | 8:25 AM EST
Shares of ILMN downgraded to Neutral from Outperform, Wedbush said. $52 price target. Diminished risk/reward due to gain in share price...
Jan 04, 2013 | 7:44 AM EST
ILMN was upgraded from Neutral to Overweight, Piper Jaffray said. $61 price target. Company can continue to gain market share in next-g...
Nov 26, 2012 | 6:54 AM EST
ILMN was downgraded from Outperform to Neutral, Robert Baird said. $54 price target. Company faces more near-term challenges.
&nb...
| Oct 11, 2012 | 6:44 PM EDT
We are shifting from a multi-position, swing-trading approach to a shorter-term approach.
Jul 23, 2012 | 7:44 AM EDT
ILMN was upgraded from Market Perform to Outperform, Leerink Swann said. Company has multiple potential catalysts.
